Rapamycin sensitizes Akt inhibition in malignant human breast epithelial cells

Cancer Letters

Volumn 296, Issue 1, 2010, Pages 74-87

  Zheng, Jie ^a   Hudder, Alice ^a   Zukowski, Kim ^a   Novak, Raymond F ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

A 443654; Cell cycle and apoptosis; Combined effects of mTOR and Akt inhibition on cell function; Combined mTOR and Akt inhibition; Combined mTOR and Akt inhibition effects on MCF10A and MCF10CA1a cell morphology; MCF10CA1a cells; Rapamycin

Indexed keywords

A 443654; CYCLIN DEPENDENT KINASE INHIBITOR 2B; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN BAD; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN P53; RAPAMYCIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL LEVEL; CELL PROLIFERATION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; ENZYME ACTIVATION; EPITHELIAL CELLS; FEMALE; FIBROCYSTIC BREAST DISEASE; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; INDAZOLES; INDOLES; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS C-AKT; SIROLIMUS; SURVIVORS;

EID: 77954762338     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.03.018     Document Type: Article

References (37)

1. Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E., Feuer E.J., Thun M.J. Cancer statistics. CA Cancer J. Clin. 2004, 54:8-29.
2. Higgins M.J., Wolff A.C. Therapeutic options in the management of metastatic breast cancer. Oncology (Williston Park) 2008, 22:614-623.
3. Jones S.E. Metastatic breast cancer: the treatment challenge. Clin. Breast Cancer 2008, 8:224-233.
4. Santner S.J., Dawson P.J., Tait L., Soule H.D., Eliason J., Mohamed A.N., Wolman S.R., Heppner G.H., Miller F.R. Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res. Treat. 2001, 65:101-110.
5. Strickland L.B., Peter J., Santner S.J. Progression of premalignant MCF10AT generates heterogeneous malignant variants with characteristic histologic types and immunochemical markers. Breast Cancer Res. Treat. 2000, 64:235-240.
6. Steven J.S., D P.J., Tait L. Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res. Treat. 2001, 65:101-110.
7. Miller R.F. Xenograft models of premalignant breast disease. J. Mammary Gland Biol. Neoplasia 2000, 5:379-391.
8. Dancey J.E. Inhibitors of the mammalian target of rapamycin. Expert Opin. Investig. Drugs 2005, 14:313-328.
9. Mita M.M., Mita A., Rowinsky E.K. Mammalian target of rapamycin: a new molecular target for breast cancer. Clin. Breast Cancer 2003, 4:126-137.
10. Kasukabe T., Okabe-Kado J., Kato N., Sassa T., Honma Y. Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts. Breast Cancer Res. 2005, 7:R1097-1110.
11. Yu K., Toral-Barza L., Discafani C., Zhang W.G., Skotnicki J., Frost P., Gibbons J.J. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr. Relat. Cancer 2001, 8:249-258.
12. Noh W.C., Mondesire W.H., Peng J., Jian W., Zhang H., Dong J., Mills G.B., Hung M.C., Meric-Bernstam F. Determinants of rapamycin sensitivity in breast cancer cells. Clin. Cancer Res. 2004, 10:1013-1023.
13. Oshiro N., Yoshino K., Hidayat S., Tokunaga C., Hara K., Eguchi S., Avruch J., Yonezawa K. Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cells 2004, 9:359-366.
14. Albert J.M., Kim K.W., Cao C., Lu B. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol. Cancer Ther. 2006, 5:1183-1189.
15. Chan S., Scheulen M.E., Johnston S., Mross K., Cardoso F., Dittrich C., Eiermann W., Hess D., Morant R., Semiglazov V., Borner M., Salzberg M., Ostapenko V., Illiger H.J., Behringer D., Bardy-Bouxin N., Boni J., Kong S., Cincotta M., Moore L. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. 2005, 23:5314-5322.
16. Beuvink I., Boulay A., Fumagalli S., Zilbermann F., Ruetz S., O'Reilly T., Natt F., Hall J., Lane H.A., Thomas G. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005, 120:747-759.
17. Luo Y., Shoemaker A.R., Liu X., Woods K.W., Thomas S.A., de Jong R., Han E.K., Li T., Stoll V.S., Powlas J.A., Oleksijew A., Mitten M.J., Shi Y., Guan R., McGonigal T.P., Klinghofer V., Johnson E.F., Leverson J.D., Bouska J.J., Mamo M., Smith R.A., Gramling-Evans E.E., Zinker B.A., Mika A.K., Nguyen P.T., Oltersdorf T., Rosenberg S.H., Li Q., Giranda V.L. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol. Cancer Ther. 2005, 4:977-986.
18. Han E.K., Leverson J.D., McGonigal T., Shah O.J., Woods K.W., Hunter T., Giranda V.L., Luo Y. Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition. Oncogene 2007, 26:5655-5661.
19. Soule H.D., Maloney T.M., Wolman S.R., Peterson W.D., Brenz R., McGrath C.M., Russo J., Pauley R.J., Jones R.F., Brooks S.C. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line MCF-10. Cancer Res. 1990, 50:6075-6086.
20. Russo J., Tait L., Russo I.H. Morphological expression of cell transformation induced by c-Ha-ras oncogene in human breast epithelial cells. J. Cell Sci. 1991, 99(Pt 2):453-463.
21. Basolo F., Elliott J., Tait L., Chen X.Q., Maloney T., Russo I.H., Pauley R., Momiki S., Caamano J., Klein-Szanto A.J., et al. Transformation of human breast epithelial cells by c-Ha-ras oncogene. Mol. Carcinogen. 1991, 4:25-35.
22. Kim S.H., Miller F.R., Tait L., Zheng J., Novak R.F. Proteomic and phosphoproteomic alterations in benign, premalignant and tumor human breast epithelial cells and xenograft lesions biomarkers of progression. Int. J. Cancer 2009, 124:2813-2828.
23. Lacroix M., Toillon R.A., Leclercq G. p53 and breast cancer an update. Endocr. Relat. Cancer 2006, 13:293-325.
24. Chagpar A.B. Advances in the management of localized breast cancer: an overview. J. Kentucky Med. Assoc. 2004, 102:202-208.
25. Coley H.M. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat. Rev. 2008, 34:378-390.
26. Zhou X., Tan M., Stone Hawthorne V., Klos K.S., Lan K.H., Yang Y., Yang W., Smith T.L., Shi D., Yu D. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin. Cancer Res. 2004, 10:6779-6788.
27. Harrison D.E., Strong R., Sharp Z.D., Nelson J.F., Astle C.M., Flurkey K., Nadon N.L., Wilkinson J.E., Frenkel K., Carter C.S., Pahor M., Javors M.A., Fernandez E., Miller R.A. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009, 460:392-395.
28. Selman C., Tullet J.M., Wieser D., Irvine E., Lingard S.J., Choudhury A.I., Claret M., Al-Qassab H., Carmignac D., Ramadani F., Woods A., Robinson I.C., Schuster E., Batterham R.L., Kozma S.C., Thomas G., Carling D., Okkenhaug K., Thornton J.M., Partridge L., Gems D., Withers D.J. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 2009, 326:140-144.
29. Kurmasheva R.T., Harwood F.C., Houghton P.J. Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors. Mol. Cancer Ther. 2007, 6:1620-1628.
30. Lu Y., Wang H., Mills G.B. Targeting PI3K-AKT pathway for cancer therapy. Rev. Clin. Exp. Hematol. 2003, 7:205-228.
31. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Brit. J. Cancer. 2004, 91:1420-1424.
32. Mondesire W.H., Jian W., Zhang H., Ensor J., Hung M.C., Mills G.B., Meric-Bernstam F. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin. Cancer Res. 2004, 10:7031-7042.
33. Law B.K., Chytil A., Dumont N., Hamilton E.G., Waltner-Law M.E., Aakre M.E., Covington C., Moses H.L. Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells. Mol. Cell. Biol. 2002, 22:8184-8198.
34. Hall M.N. mTOR-what does it do?. Transplant Process. 2008, 40:S5-8.
35. Breuleux M., Klopfenstein M., Stephan C., Doughty C.A., Barys l., Maira S-M., Kwiatkowski D., Lane H.A. Increased Akt S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol. Cancer Ther. 2009, 8:742-753.
36. 2481 is a marker for intact mTOR signaling complex 2. Cancer Res. 2009, 69:1821-1827.
37. Costa R.L. Targeted Therapy: Comprehensive Review. Am. J. Hospice Palliat. Care. 2009.